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Abstract: Metabolic syndrome is characterized by a combination of obesity, hypertension, 
insulin resistance, dyslipidemia, and impaired glucose tolerance. This multifaceted syndrome 
is often accompanied by a hyperdynamic circulatory state characterized by increased blood 
pressure, total blood volume, cardiac output, and metabolic tissue demand. Experimental, epide-
miological, and clinical studies have demonstrated that patients with metabolic   syndrome have 
significantly elevated cardiovascular morbidity and mortality rates. One of the main and 
frequent complications seen in metabolic syndrome is cardiovascular disease. The primary 
endpoints of cardiometabolic risk are coronary and peripheral arterial disease,   myocardial 
infarction, congestive heart failure, arrhythmia, and stroke. Alterations in expression and/or 
functioning of several key proteins involved in regulating and maintaining ionic homeostasis 
can cause cardiac disturbances. One such group of proteins is known as ryanodine receptors 
(intracellular calcium release channels), which are the major channels through which Ca2+ 
ions leave the sarcoplasmic reticulum, leading to cardiac muscle contraction. The economic 
cost of metabolic syndrome and its associated complications has a significant effect on health 
care budgets. Improvements in body weight, blood lipid profile, and hyperglycemia can reduce 
cardiometabolic risk. However, constant hyperadrenergic stimulation still contributes to the 
burden of disease. Normalization of the hyperdynamic circulatory state with conventional 
therapies is the most reasonable therapeutic strategy to date. JTV519 (K201) is a newly devel-
oped 1,4-benzothiazepine drug with antiarrhythmic and cardioprotective properties. It appears 
to be very effective in not only preventing but also in reversing the characteristic myocardial 
changes and preventing lethal arrhythmias. It is also a unique candidate to improve diastolic 
heart failure in metabolic syndrome.
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Metabolic syndrome
Metabolic syndrome is characterized by a combination of obesity, hypertension, 
insulin resistance, dyslipidemia, and impaired glucose tolerance.1 The mechanisms 
responsible appear to be multifactorial, and include family history, physical inactivity, 
and a sedentary lifestyle. Key market players spend millions of dollars developing 
new therapeutic strategies against components of metabolic syndrome and its related 
complications. The challenge in this area is that the emerging therapeutic agents 
seem not to be very effective in treating obesity and insulin resistance or reducing 
further cardiometabolic risk.2 This multifaceted syndrome is often accompanied by a 
h  yperdynamic circulatory state characterized by increased blood pressure, total blood 
volume, cardiac output, and metabolic tissue demand.3–10 Hypertension generally 
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amplifies the high cardiovascular risk if the disease remains 
uncontrolled for a long time.11–15
Experimental, epidemiological, and clinical studies have 
demonstrated that patients with metabolic syndrome have sig-
nificantly elevated cardiovascular morbidity and mortality.10–17 
Hypertension and changes in heart rate generally appear 
early on, with the risk of developing coronary artery dis-
ease, arteriosclerosis, and heart failure increasing at a later 
stage.3–10,16 In the end, making a decision regarding “which 
aggravates which first” is complicated. All these assessments 
aim to generate the best treatment modalities which provide 
a better health care strategy in a cost-effective manner. The 
basic therapeutic approach still focuses on decreasing body 
weight (adipose tissue mass) and hepatic fat deposition. Diet, 
exercise, and lifestyle modification are out of professional 
control in most cases, because they depend on the patient’s 
intellectual capacity and their economic situation. Coping 
with all these strategies requires good patient monitoring with 
conventional and/or new therapeutic agents.
Newly identified compounds should aid in the manage-
ment of body weight with improvement in blood glucose in 
patients with diabetes.18 Randomized controlled clinical trials 
have shown that exenatide, a glucagon-like peptide analog, 
is effective in reducing glycemic events and assisting with 
beneficial weight loss.2,19 Nausea is a known side effect of 
this drug, along with rare cases of pancreatitis, but its side 
effect profile still lies within the acceptable range.19 The other 
newer agents, ie, the dipeptidyl peptidase-4 (DPP-4) inhibi-
tors (sitagliptin and vildagliptin) combined with metformin, 
glitazone, and sulfonylurea in clinical trials have been shown 
to be very effective for blood glucose control.2,18,20 The trials 
indicate that these agents are associated with fewer hypo-
glycemia episodes and less weight gain, and that they are 
also an effective intervention to decrease obesity. On the 
other hand, less information is available about whether they 
have any beneficial effects on cardiovascular complications. 
However, some knowledge already exists showing that they 
reduce glycosylated hemoglobin (HbA1c) levels by a couple of 
percentage points and decrease hyperglycemic/hypoglycemic 
episodes, especially nocturnal ones.18,20 However, further data 
are required to assess their long-term efficacy and tolerabil-
ity in clinical trials to determine their exact cardiovascular 
benefits in metabolic syndrome.
Cardiovascular dysfunction  
in metabolic syndrome
Obesity and metabolic syndrome can cause   cardiovascular 
complications.1,3–10,13,16,21–24 The underlying molecular 
  mechanisms responsible could be related to the development 
of a hyperdynamic circulatory state, which may trigger a 
variety of cardiac and hemodynamic changes. To date, from 
metabolic syndrome through diabetes, a new treatment 
paradigm is emerging. To cope with the complications 
associated with metabolic syndrome, early diagnosis of the 
disease is essential. Despite an increase in the diagnosed/
undiagnosed ratio in recent years, they have to treat with 
new updated therapeutic guidelines to protect against 
complications.21,23–25 Under these circumstances, a poor 
diet secondary to a sedentary lifestyle without appropriate 
treatment increases cardiometabolic risk. The basic treat-
ment strategies still appear as simple as ever, and include 
control of body weight, blood pressure m  anagement, and 
normalization of blood lipids, with maintenance of nor-
moglycemia. The link between metabolic syndrome and 
cardiovascular risk is clear, but the underlying molecular 
mechanisms need to be investigated to assist our treatment 
decisions.
The main consequences of the cardiometabolic risk pro-
file are coronary and peripheral arterial disease, myocardial 
infarction, congestive heart failure, arrhythmia, and stroke.10 
However, because overweight and obesity are independent 
risk factors, insulin resistance and lipid disturbances appear to 
be integral components of the disease.10,14,18 Reduced HbA1c, 
low-density lipoprotein cholesterol and triglycerides and 
increased high-density lipoproteins are already well known 
to lower cardiometabolic risk.
Cardiac ryanodine receptors
Alterations in the expression and/or function of several 
key proteins involved in regulating and maintaining ionic 
homeostasis can cause cardiac disturbances. One such group 
of proteins is called the ryanodine receptors (RyRs), which 
are a component of the intracellular Ca2+ release channels 
located in the membrane of the sarcoplasmic reticulum.4,26,27 
Three isoforms have been identified in the human heart, and 
are referred to as type 1, 2, and 3 (RyR1, RyR2, and RyR3, 
respectively).27,28 Type 2 ryanodine receptors are the major 
release channels through which Ca2+ leaves the sarcoplasmic 
reticulum and leads to cardiac muscle contraction.28 Rapid 
depolarization of the sarcoplasmic reticulum membrane in 
the heart by Ca2+ via the RyR2 receptor is an important step 
in cardiac contractility. However, the physiological role of 
the RyR1 and RyR3 isoforms also expressed in the human 
heart remains unclear.27
RyR2 is a homotetramer comprising four 565 kDa mono-
mers, each containing a transmembrane segment.28 The RyR2 
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receptor normally closes at low cytosolic Ca2+ levels during 
diastole. However, submicromolar cytosolic Ca2+ levels 
increase the probability of the channel being open with 
high-affinity binding sites available.4,28–32 A plant alkaloid 
ryanodine isolate, Ryania speciosa, found in central and 
South America, locks the RyR2channel in a subconductance 
state and induces paralysis, and was previously tested as an 
insecticide.28 Subsequently, ryanodine was used to purify 
RyR2 from the sarcoplasmic reticulum as a high-affinity 
ligand.28,33 Beyond that, no therapeutic indication has been 
identified as yet which would warrant its development as a 
pharmaceutical product.
The calcium channel binding protein, FKBP12.6 (12.6 kDa 
FK506-binding protein) binds to RyR2 and stabilizes the 
closed state of the channel, and has recently been renamed 
as calstabin 2.34–36 Dissociation of FKBP12.6 from RyR2 
increases the open probability of the channel.28   Furthermore, 
genetic deletion of calstabin 2 enhances Ca2+ release from 
the sarcoplasmic reticulum and causes leaky RyR2.28   Protein 
kinase A and calcium/calmodulin dependent kinase A 
(CaMKII) phosphorylate serine 2809 (Ser2809) and Ser2814, 
respectively, on RyR2.37–39 However, many different phospho-
rylation sites (Ser2808, Ser2809, Ser2814, Ser2815, and Ser2030) have 
now been reported for both these enzymes across different 
species.37–39 Phosphorylation of RyR2 by protein kinase A 
causes increased sensitivity of RyR2 to intracellular Ca2+, dis-
sociation of calstabin 2 from the channel, and enhanced RyR2 
activity,40 leading to an increase in the open probability of the 
channel. Recent evidence has demonstrated that nitrosylation 
and/or oxidation of RyR2 also alters the binding affinity of 
calstabin 2, which affects channel activity.41,42 CaMKII is also 
a holoenzyme which sensitizes the channel to cytosolic Ca2+ 
and increases the open probability of the channel, but does 
not dissociate calstabin 2 from the channel.39
Other modulatory proteins, ie, phosphodiesterase 4D3 
(PDE4D3), calmodulin, protein phosphatase 1 and 2a, and 
sorcin, modulate the N terminal cytoplasmic domain of RyR2, 
which includes calstabin 2, protein kinase A, and CaMKII.28 
PDE4D3 binds to kinase-anchoring protein, which is part 
of the RyR2 macromolecular complex and degrades cyclic 
adenosine monophosphate (cAMP). Protein kinase A also 
binds kinase-anchoring protein to regulate local cAMP levels 
near the channel, as does PDE4D3. Protein phosphatase 1 and 
2a dephosphorylate phosphorylated channels via spinophilin 
and PR130, respectively, and indirectly regulate channel 
activity. Protein phosphatase 1 predominantly dephospho-
rylates Ser2808 and Ser2809, while protein phosphatase 2a 
dephosphorylates Ser2814. Many of these modulatory proteins 
can prevent or ameliorate the probability of the channel being 
open, thereby contributing directly to cardiac contraction.28
Nevertheless, calmodulin, a 17 kDa protein, assists in the 
closing state of RyR2, binding 3583–3603 amino acids after 
Ca2+ release from the sarcoplasmic reticulum during excita-
tion-contraction coupling, which basically inhibits RyR2.43–45 
Sorcin, a 22 kDa Ca+ binding protein, also reduces the open 
probability of RyR2, which decreases the amplitude of Ca2+ 
release from the sarcoplasmic reticulum without affecting 
L-type Ca2+ current when Ca2+ levels are elevated.46,47 
Calsequestrin, junctin, and triadin are modulatory proteins 
related to the C terminus which form a complex with RyR2 
in the lumen of the sarcoplasmic reticulum.28,48   Calsequestrin 
sequesters Ca2+ in the sarcoplasmic reticulum, causing an 
increase in the open probability of RyR2.28 Triadin and junctin 
link calsequestrin to the channel and normalize the Ca2+ load 
in the sarcoplasmic reticulum.28 Current strategies for the 
management of cardiac disturbances do not focus directly 
on RyR2 and no relevant molecule has been approved as yet 
anywhere in the world. Several attempts at developing RyR2 
as a therapeutic molecule have been made in the past, but 
were unable to demonstrate efficacy and safety.
Ryanodine receptor dysfunction  
in metabolic syndrome
Obesity and its associated comorbidities affect almost 
one third of the population of the western world, and their 
prevalence tends to increase each year. The economic cost of 
metabolic syndrome and its complications have a significant 
impact on health care budgets worldwide. The most com-
mon complications seen in metabolic syndrome are cardio-
vascular in nature, and include arrhythmias, hypertension, 
and coronary artery disease. While improvements in body 
weight, blood lipid profile, and hyperglycemia can reduce the 
cardiometabolic risk, constant hyperadrenergic stimulation 
still contributes to the burden of the disease.
One of the mechanisms underpinning the increased 
cardiometabolic risk in metabolic syndrome is impaired 
Ca2+ storage in the sarcoplasmic reticulum and diastolic 
Ca2+ leak during hypersympathetic stimulation.4,16 It is 
assumed that treatment should aim to restore the normal 
hyperphosphorylation state involving excitation-contraction 
coupling proteins, such as RyR2.3,4,9,16 Many laboratories 
have found basal catecholamine levels to be elevated in 
metabolic syndrome.3,4,9,10,12,16,25,49 We have also previously 
  demonstrated that induction of metabolic syndrome by 
chronic high-fat feeding increases circulating plasma epi-
nephrine levels by 55% and norepinephrine levels by 31%.3 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
91
Cardiac ryanodine receptors in metabolic syndromeDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
Chronic activation of the sympathetic nervous system, 
as occurs in metabolic syndrome, leads to increased protein 
kinase A-mediated phosphorylation of RyR2 at Ser2809 and 
Ser2808 (see Figure 1).3–5,16 Recent experimental evidence sug-
gests that chronic hyperphosphorylation of RyR2 contributes 
to impaired contraction, generation of lethal ventricular 
arrhythmias, and development of heart failure via leaky 
RyR2 channels.50
We have recently demonstrated that the functional 
integrity of RyR2 is compromised by metabolic syndrome, 
as evidenced by augmented RyR2 phosphorylation together 
with diminished RyR2 binding affinity.4 RyR2 Ser2809 and 
RyR2 Ser2808 phosphorylation sites have been used widely 
as an index of RyR2 phosphorylation by protein kinase 
A. Other studies have demonstrated that CaMKII also 
phosphorylates the RyR2 (Ser2814 or Ser2815) molecule, and 
that CaMKII can activate RyR2 gating but not at protein 
kinase A (Ser2808 or Ser2809) sites, preventing dissociation 
of FKBP12.6 from RyR2 (see Figure 1). Protein kinases C 
and G can also phosphorylate the RyR2 molecule.28,39,40,51–53 
Protein kinase C-mediated and protein kinase G-mediated 
pathways are mainly responsible for phosphorylation of the 
Ser2030 RyR2 molecule, which can also be phosphorylated 
by protein kinase A but is certainly a poor substrate for 
CaMKII.28,35,51,54 Increased sympathetic nervous system 
activity could be a mechanism by which metabolic syn-
drome leads to impaired RyR2 function. The possibility 
of phosphorylation of RyR2 sites by different pathways in 
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Figure 1 Schematic diagram of RyR2 dysfunction in metabolic syndrome. Cardiac RyR2 dysfunction seen in metabolic syndrome (MetS) could be related to the cAMP/PKA-
dependent pathway under constant hyper adrenergic stimulation. increased Ser2809 phosphorylation of cardiac RyR2 in MetS is possibly mediated by PKA activation. increase 
in circulating catecholamine stimulates G-protein-coupled b-ARs thereby activating intracellular cyclic adenosine monophosphate (cAMP) and PKA. JTV-519 (K201) increases 
binding affinity of FKBP12.6 to RyR2, which stabilizes the closes state of RyR2 channels and prevents Ca++ leak which protects from ventricular arrhythmias, contractile 
dysfunction and reduce Ca++ overload. 
Abbreviations: SR, sarcoplasmic reticulum; b1–AR, adrenoreceptor; b2–AR, adrenoreceptor; Gsa, stimulatory protein G alpha; Gia , inhibitory protein alpha; AC, adenyle 
cyclase; PDE4, phosphodiesterase 4; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; mKAP, a kinase anchoring protein; CaMKii, calcium/calmodulin 
dependent kinase ii; Ser 2808, Serin2808; Ser 2814, Serine2814.
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different species has not been clearly defined as yet, and 
needs to be investigated.
The cardiac RyR2 dysfunction seen in metabolic syndrome 
could be related to a cAMP/protein kinase A-  dependent 
pathway under constant hyperadrenergic stimulation (see 
Figure 1).2–5,16 Increased Ser2809 phosphorylation of cardiac 
RyR2 in metabolic syndrome is possibly mediated by acti-
vation of protein kinase A, whereby there is an increase in 
circulating catecholamines which stimulate G protein-coupled 
b-adrenoceptors, thereby activating intracellular cAMP and 
protein kinase A (see Figure 1). This hypothesis is supported 
by earlier studies in which chronic sympathetic activation 
resulted in protein kinase A-mediated   hyperphosphorylation of 
RyR2.28,54,55 Earlier studies indicate that constant sympathetic 
nervous system activity can switch the predominant cardiac 
signaling pathway from protein kinase A to CaMKII.28,37,51,56 
Whether metabolic syndrome alters signaling pathway 
through the protein kinase A or CaMKII is presently unknown; 
however, Xiao et al recently demonstrated that constant 
b-adrenoreceptor stimulation switches the signaling pathway 
from being predominantly protein kinase A-driven to being 
mainly CaMKII-driven.50,53
We have also demonstrated that metabolic syndrome 
compromises only the functional integrity of the cardiac 
RyR2 receptor without downregulation, as evidenced by 
diminished binding affinity and no change in mRNA or 
protein expression.4 Changes in modulatory proteins that 
could also contribute to impaired functional integrity of 
RyR2 include altered dissociation of FKBP12.6 and/or 
PDE4D3 deficiency. However, whether these modulatory 
proteins contribute to impaired functional integrity of RyR2 
in metabolic syndrome is unknown.
The majority of patients with metabolic syndrome have 
absolute or relative insulin deficiency (diabetes), including 
hyperinsulinemia, dyslipidemia, and dysregulation of the 
renin-angiotensin system. These parameters compromise 
the molecular levels of myocytes, including RyR2 and 
sarco(endo)plasmic reticulum Ca2+-ATPase. Direct and indi-
rect effects of glucotoxicity trigger overproduction of reactive 
oxygen species, poly(ADP-ribose) polymerase, and advanced 
glycation end-products, and induce   apoptosis.57 They cause 
altered expression and function of RyR2 via post-translational 
modifications of extracellular matrix components, which 
contribute to systolic and diastolic dysfunction.57,58 Hyper-
glycemia causes two types of post-translation modifications 
on RyR2 and sarco(endo)plasmic reticulum Ca2+-ATPase; 
first, it increases production of reactive oxygen species 
(superoxide anions, hydroxyl radicals, lipid peroxides, 
hydrogen peroxide) and, second, it increases reactive nitrogen 
species (nitrosonium cation, nitroxyl anion, peroxynitrite).32,59 
These free radical and nonradical species alter the tertiary 
structure of RyR2, causing RyR2 to become sensitive to 
endogenous ligands, such as Ca2+ and adenosine triphosphate 
(ATP).32,59 We have previously demonstrated that advanced 
glycation end-products are formed on intracellular RyR2 
during diabetes; however, treatment with insulin minimizes 
these nonenzymatic products, which attenuate protein activi-
ty.32 RyR2 is a large transmembrane and long-lived protein 
(approximately eight days). It localizes in the sarcoplasmic 
reticulum and plays a critical role in cardiac excitation-
contraction coupling. When advanced glycation end-product 
complexes attenuate the RyR2 protein, the changes are 
permanent.31,32,59 For that reason, an oral hypoglycemic or 
insulin treatment-focused therapeutic strategy is not able to 
restore cardiac contraction.
Dyslipidemia is the other major component of metabolic 
syndrome and characterized by increased circulating fatty 
acids and triglycerides,57 causing cardiac lipotoxicity and 
accumulation of fatty acids in cardiomyocytes which, in 
turn, leads to increased shortening of the action   potential 
in the K-ATP channel and dysregulation of the open 
  probability in the RyR2 channel. It also causes diminished 
cycling of the L-type Ca2+ channel and reduction of Ca2+ 
stores in the sarcoplasmic reticulum.57 Chronic lipid accu-
mulation in cardiomyocytes also contributes to apoptosis 
via inhibition of the mitochondrial respiratory chain if 
fatty acids are not completely metabolized.57,60 However, 
intracardiac fatty acid accumulation enhances oxygen 
demand and generation of reactive oxygen species, and 
diminishes ATP synthesis because of mitochondrial 
  dysfunction.60 In the normal subject, the heart obtains energy 
for cardiac contractility from fatty acid oxidation, but in 
a hyperinsulinemic state, the need for myocardial glucose 
decreases significantly and shifts fatty acid synthesis to the 
b-oxidation pathway, causing secondary dysregulation of 
open probability of the RyR2 channel.61
The chronic hyperinsulinemia seen in metabolic syn-
drome also activates the sympathetic nervous system and the 
renin angiotensin system indirectly through crosstalk between 
insulin-dependent signaling and cardiac progrowth pathways, 
via similar common elements in their molecules.57 Insulin 
activates a signaling cascade with neurohormonal growth 
agonists, eg, insulin like growth factor 1 and   angiotensin 
II, which coordinate cell growth and protein synthesis 
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activated by extracellular signal-regulated kinase, and the 
phosphoinositol-3 kinase/protein-kinase B cascade associ-
ated with physiological cardiac hypertrophy.62 Both these 
pathways also activate the sympathetic nervous system and 
the   renin-angiotensin system via trigger adrenergic and AT1 
receptors, as well as the angiotensin II pathway in the hyper-
insulinemic state.57 Constant hyperadrenergic stimulation 
further activates intracellular cAMP and protein kinase A, 
thereby causing hyperphosphorylation of RyR2 and mild to 
moderate leaky channels (see Figure 1).28,35,54,55   Decreasing 
the binding affinity of FKBP12.6 to RyR2 increases the 
probability of open RyR2 channels, and Ca2+ leak is seen 
during diastole. Ventricular arrhythmias, contractile 
  dysfunction, and Ca2+ overload is triggered as part of that 
pathology.35,37,54,55,57
Cardiac hypertrophy and heart failure have been reported 
in patients with hypertension, diabetes, insulin resistance, 
and obesity, and increased sympathetic nervous system and 
renin-angiotensin system activity is well demonstrated in 
these patients. Indeed, the main complexity in therapeutic 
disadvantages is the indirect contribution of chronic 
hyperinsulinemia to already overstimulated adrenergic and 
angiotensin II pathways, and requires long-term follow-up 
studies. Intensive glucose control has demonstrated an indirect 
correlation with decreased cardiovascular complications, 
including hypertension, myocardial infarction, and 
stroke. This clearly answers the important question of which 
comes first, ie, whether overinsulinization triggers the central 
nervous system indirectly or whether the central nervous 
system could operate as a main driver of hyperinsulinemia.
Dysregulation of intracellular Ca2+ homeostasis has been 
reported previously in situations of abnormal membrane lipid 
content, glucotoxicity, and hyperinsulinemia, as well as in 
hyperadrenergic states.49,57,58 Alterations in the expression 
and function of sarco(endo)plasmic reticulum Ca2+-ATPase, 
the Na-K-ATPase Na+/Ca2+ exchanger, and RyR2 have been 
identified in these patient groups, and associated with 
hypertension, type 1 and 2 diabetes mellitus, obesity, and 
dyslipidemia.28,57,58 Although metabolic syndrome does 
not always coexist with type 2 diabetes, obesity alone 
can increase the risk of developing type 2 diabetes and 
this in turn increases diabetes-associated cardiovascular 
complications.49
Future therapeutic concepts
Until recent years, normalization of the hyperdynamic cir-
culatory state in metabolic syndrome using conventional 
therapies, such as adrenergic receptor blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, 
and calcium channel blockers, was the most reasonable 
therapeutic strategy (see Figure 1).2,4,5 Other important aims 
were to reduce body weight, increase exercise capacity, 
restore a normal plasma lipid profile, and improve meta-
bolic biomarkers. However, in spite of normalizing these 
parameters, cardiometabolic risk remains mostly irreversible 
if the disease continues in the long term.2–5 Cardioselective 
b1-adrenoreceptor blockers control heart rate and aortic 
pressure, and decrease the cardiac index, especially dur-
ing exercise (Figure 1). We recently documented that basal 
cate  cholamine levels are elevated in metabolic syndrome.3   
It is very clear that adrenergic receptor blockers can normalize 
the increased sympathetic nervous system activity, thereby 
at least being able to protect the RyR2 channel against Ca2+ 
leak during diastole.
The b1-adrenoceptor blockers, angiotensin-converting 
enzyme inhibitors, and angiotensin receptor blockers 
suppress the hyperadrenergic state, thereby restoring the 
stoichiometry of the RyR2 channel. Many studies, including 
CONSENSUS, SOLVD-T, Val-HeFT, and CHARM, have 
demonstrated that angiotensin receptor blockers are more 
effective than angiotensin-converting enzyme inhibitors in 
congestive heart failure.63–65 In the Val-HeFT trial, angiotensin 
receptor blockers reduced the heart failure hospitalization 
rate when added to conventional therapy, including an 
angiotensin-converting enzyme inhibitor in most patients, 
but had no effect on mortality.66,67 The CHARM trial dem-
onstrated that an angiotensin receptor blocker reduced mor-
bidity and mortality as a result of reduced systolic function 
with or without combination with an angiotensin-converting 
enzyme inhibitor,66,67 indicating that this treatment strategy 
is beneficial and preserves left ventricular systolic function. 
Adrenergic receptor blockers and angiotensin-converting 
enzyme inhibitors were compared head-to-head in patients 
with congestive heart failure in clinical trials such as ELITE 
I and ELITE II.66,67 There have been some clinical trials of 
an angiotensin-converting enzyme inhibitor combined with 
digoxin, diuretics (SOLD-T), and a b1-adrenoceptor blocker 
(CIBIS-2).63,64,66,67 One-year   mortality-related improvement 
in survival in patients with congestive heart failure was 
found to be better in patients who received combination 
angiotensin receptor blocker and angiotensin-converting 
enzyme inhibitor therapy, eg, in the CHARM-Added trial 
(diuretic + digoxin + angiotensin-  converting enzyme inhibi-
tor + b1-adrenoceptor blocker + angiotensin receptor blocker) 
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if compared with SOLD-T (diuretic + digoxin + angio-
tensin-converting  enzyme  inhibitor)  and  CIBIS-2 
(diuretic + digoxin + angiotensin-converting enzyme 
inhibitor + b1-adrenoceptor blocker).65 Overall, the clini-
cal trials demonstrated that combination of an adrenergic 
receptor blocker + angiotensin-converting enzyme inhibitor 
produced better outcomes for patients with congestive heart 
failure, in terms of cardiovascular mortality risk and hospital 
admissions.
These treatment regimes can restore sympathovagal bal-
ance and can reverse remodeling in the failing heart, as evi-
denced by a significant reduction in left ventricular volume and 
an improved contractile response.63–65,67 The b1-adrenoceptor 
blockers failed to meet the necessary safety profile in meta-
bolic syndrome and diabetes because they can affect glyco-
genolysis, interfere with insulin release, further impair glucose 
tolerance, and increase serum triglycerides.68 For these rea-
sons, angiotensin receptor blockers, angiotensin-converting 
enzyme inhibitors or combinations of these agents fit better 
in the treatment regime.66,67 In fact, these algorithms could be 
used in clinical trials of metabolic syndrome to explore the 
most beneficial pharmaceutical strategies.
JTV519 (K201) is a promising, newly developed 1, 
4-benzothiazepine drug and a nonspecific blocker of Na+, K+, 
and Ca2+ channels, with antiarrhythmic and cardioprotective 
properties.69 Like diltiazem, JTV519 blocks the L-type Ca2+ 
current, but is not classified as a Ca2+ channel blocker.69,70 
Rather than acting as a b-adrenoceptor blocker, it blocks 
a1-receptors and intracellular Ca2+ pathways.69,70 It is a 
relatively nonselective blocker of cation currents, including 
the Na+ current (INA) in a voltage-dependent and frequency-
dependent manner.71,72 The time course of Na+ current block-
ade with JTV519 is slower than with lidocaine, similar to 
quinidine, and is believed to have intermediate rather than 
fast kinetics.70 It also blocks the inward rectifying K+ current 
(IK1) and rapidly activating component of the delayed recti-
fied K+ current (IKr), but not the slowly activating component 
(IKs).73 JTV519 blocks the Ca2+ current (ICa) and muscarinic 
acetylcholine receptor-operated K+ current (IKAch).70,73
JTV519 stabilizes the closed state of RyR2 and increases 
the binding affinity of FKBP12.6 for RyR2 (see Figure 1), 
thereby reducing and preventing Ca2+ leak, and protecting 
against ventricular arrhythmia, contractile dysfunction, and 
Ca2+ overload.2,16,26,69,74 This beneficial combination of activity 
dramatically ameliorates the progression of heart failure as 
a result of myocardial damage resulting from Ca2+ overload. 
The most recent evidence shows that JTV519 protects against 
Ca2+ leak from the sarcoplasmic reticulum independent of 
the interaction between FKBP12.6 and RyR2.75 Spontaneous 
sarcoplasmic reticulum Ca2+ release (leak) also occurs when 
the Ca2+ content in the sarcoplasmic reticulum reaches a 
threshold level, ie, overload of Ca2+ stores in the sarcoplasmic 
reticulum,75 and is known as store overload-induced Ca2+ 
release (SOICR), which is independent of FKBP12.6 binding 
to RyR2.70,75 SOICR causes delayed after depolarizations and, 
in turn, arrhythmias, such as those seen in catecholaminergic 
polymorphic ventricular tachycardia and arrhythmogenic 
right ventricular dysplasia type 2.70,75
Since 2000, JTV519 has been investigated in Phase II trials 
for its ability to protect against acute myocardial    infarction, 
and is suggested to reduce reperfusion injury following 
percutaneous transluminal coronary angioplasty and 
has been shown to be protective in models of ischemia-
reperfusion injury and heart failure.76   Stabilization of RyR2 
reduces detrimental intracellular Ca2+ leak and improves 
both diastolic and systolic contractile function in the 
human heart with or without an FKBP12.6-RyR2 binding 
  interaction.75 It has also been shown that inhibition of SOICR 
by JTV519 could be a sophisticated treatment strategy 
for   catecholamine-induced or inherited forms of cardiac 
  arrhythmia (catecholaminergic polymorphic ventricular 
tachycardia and arrhythmogenic right ventricular dysplasia 
type 2).77 JTV519 prevents   myocardial infarction and sud-
den cardiac death.69,70 It provides more effective myocardial 
  protection than calcium channel blockers and b1-adrenoceptor 
blockers. JTV519 also has fewer negative inotropic and 
  chronotropic effects,69,70 and, in particular, prevents myo-
cardial injury caused by ischemia and catecholamines to 
a greater extent than do nicorandil, prazosin, propranolol, 
verapamil, and diltiazem.69,70
Metabolic syndrome is associated with a hyperdynamic 
circulatory state characterized by increased blood pres-
sure, total blood volume, cardiac output, and metabolic 
tissue demand.78,79 Many laboratories have demonstrated 
that basal catecholamine levels are elevated in metabolic 
syndrome.3,4,9,10,12,16,25,49 We have also previously shown that 
induction of metabolic syndrome by chronic high-fat feeding 
increases circulatory plasma epinephrine levels by 55% and 
norepinephrine levels by 31%.3 The hyperadrenergic state 
seen in metabolic syndrome could trigger lethal arrhythmias 
and myocardial ischemia, especially during exercise.3–5
JTV519 is a promising new drug for possible use in the 
treatment of the cardiovascular disturbances associated with 
metabolic syndrome. It is a cardioprotective agent against 
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ischemia and hyperadrenergic states for two important 
reasons; first of all, it can not only protect against but also 
reverse myocardial damage, and second, it has fewer inotropic 
and chronotropic effects than the calcium channel blockers 
and cardioselective b- adrenoceptor blockers.70 JTV519 sta-
bilizes the closed state of RyR2, is thought to increase the 
binding affinity of FKBP12.6 for RyR2, and protects car-
diomyocytes against SOICR, which is independent of the 
FKBP12.6-RyR2 interaction.70,75
JTV519 blocks cardiac INA, IK1, IKr, ICa and IKAch
70 and 
inhibits IKAch and IKr in atrial muscle cells, which are potential 
channels for atrial fibrillation.73,80 It also inhibits IKAch in the 
atrial appendage which generates atrial fibrillation, mostly 
in the sinus node.73,80 JTV519 also inhibits ventricular tachy-
cardia and fibrillation,70 and causes prolongation of the QT 
intervals. It suppresses torsades de pointes in a dose-depen-
dent manner by blocking a1-adrenoreceptors and inhibiting 
abnormal Ca2+ release from the sarcoplasmic   reticulum.70 
SOICR may also cause delayed after   depolarizations and 
contribute to development of ventricular arrhythmias.75 
Therefore, JTV519 appears to be a very good candidate as an 
antiarrhythmic agent in the treatment of atrial and ventricular 
arrhythmias in patients with metabolic syndrome, especially 
during exercise.
Another clinical application of JTV519 could be in dia-
stolic heart failure. To date, the exact etiology of diastolic 
heart failure is unknown and there are no drugs available to 
treat it. JTV519 could be a good choice because it normalizes 
left ventricular end-diastolic pressure, protects against the 
effects of catecholamines, and restores aortic valve open-
ing in the diastolic phase.69,70 Some treatment approaches 
available for systolic heart failure include digitalis, cyclic 
nucleotide phosphodiesterase inhibitors (milrinone, inamri-
none), angiotensin antagonists (angiotensin-converting 
inhibitors and receptor blockers), b-adrenoceptor agonists, 
and a-adrenoreceptor antagonists.69,70
One of the main complications seen in metabolic 
syndrome is cardiovascular disturbance, ie, hypertension, 
arrhythmias, coronary artery disease, and heart failure. Meta-
bolic syndrome is associated with a hyperdynamic circulatory 
state characterized by hypertension and increased cardiac 
output, with an enhanced cardiometabolic risk profile.4,5,16 
JTV519 stabilizes the closed state of RyR2 and increases 
the binding affinity of FKBP12.6 to RyR2.70 It also protects 
cardiomyocytes against SOICR, which is independent of the 
FKBP12.6-RyR2 interaction,75 protects against stress-induced 
cardiomyopathy,69,70 and prevents and restores myocardial 
injury more effectively than do the b-adrenoceptor blockers, 
Ca2+ channel blockers, a-adrenoreceptor antagonists, and 
vasodilator agents.70 JTV519 appears to be the most effective 
in not only preventing but also reversing myocardial altera-
tions caused by ischemia and catecholamines, protecting 
against lethal arrhythmias, and improving diastolic heart 
failure.70 It could be a future therapeutic strategy to target the 
arrhythmias, myocardial ischemia, myocardial infarction, and 
diastolic heart failure seen in metabolic syndrome.
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